Comparing Tickers & Gains - 14.14% for AVGO (Day Trader) vs 14.62% for NVAX (Swing Trader)
Analyzing Ticker Performance: AVGO vs NVAX and Compare Day Trader: Medium Volatility Stocks for Active Trading (TA&FA) 14.14% for AVGO vs Swing Trader: Medium Volatility Stocks for Active Trading (TA&FA) 14.62% for NVAX
When comparing the tickers AVGO and NVAX, it is evident that both stocks have shown impressive gains. AVGO recorded a gain of 14.14%, while NVAX outperformed slightly with a gain of 14.62%. These figures indicate that both stocks have experienced notable growth, making them attractive options for traders.
Now let's delve deeper into the price growth of these stocks and explore the industries they belong to.
Price Growth Analysis:
AVGO, which operates in the semiconductor industry, witnessed a significant price change of +9.85% during the past week. On the other hand, NVAX, operating in the biotechnology sector, had a price change of +4.81% over the same period. These numbers highlight the robust performance of both companies in their respective industries.
Industry Comparison:
The average weekly price growth for all stocks in the semiconductor industry stood at +3.49%. Looking at the monthly average, the semiconductor industry demonstrated even stronger growth with +20.60%, while the quarterly average was +28.40%. These statistics indicate a consistently positive trend for semiconductor stocks, including AVGO.
In the biotechnology industry, the average weekly price growth across all stocks was +2.15%. The monthly average for the industry was +7.69%, and the quarterly average reached an impressive +40.61%. These numbers suggest that the biotechnology sector, where NVAX operates, also experienced steady growth during the measured period.
Earnings Reporting:
Investors closely monitor earnings reports as they provide crucial insights into a company's financial health. AVGO is expected to report earnings on September 7, 2023, while NVAX's earnings report is anticipated on August 3, 2023. Traders and investors should mark these dates on their calendars to stay updated on the financial performance of these companies.
Industry Descriptions:
The semiconductor industry (@Semiconductors) exhibited a weekly average price growth of +3.49%. This sector is known for its involvement in manufacturing electronic components, including integrated circuits and transistors. The positive weekly price growth indicates a favorable environment for semiconductor stocks.
The biotechnology industry (@Biotechnology) recorded a weekly average price growth of +2.15%. Biotechnology companies focus on using living organisms or biological systems to develop products and technologies that have medical, agricultural, or industrial applications. The modest weekly price growth suggests steady progress within the biotechnology sector.
Both AVGO and NVAX have displayed strong performance, with gains of 14.14% and 14.62% respectively. AVGO, operating in the semiconductor industry, has shown a substantial price change, while NVAX, in the biotechnology sector, has also exhibited notable growth. Investors should closely monitor these stocks and consider their respective industry trends and earnings reporting dates to make informed investment decisions.
NVAX's Stochastic Oscillator sits in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Aroon Indicator entered an Uptrend today. In of 112 cases where NVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for NVAX moved out of overbought territory on May 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVAX as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on June 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
NVAX moved below its 50-day moving average on June 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NVAX crossed bearishly below the 50-day moving average on June 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NVAX broke above its upper Bollinger Band on May 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.468) is normal, around the industry mean (20.978). P/E Ratio (3.140) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). NVAX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (2.558) is also within normal values, averaging (366.957).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of novel recombinant vaccines
Industry Biotechnology
Advertisement